Company intelligence / Profile preview
Joint Biosciences Ltd.
Shanghai, Shanghai Shi / Shanghai Municipality, Chinajointbiosciences.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Joint Biosciences has initiated a Phase 1 clinical trial of its lead candidate OVV‑01, an oncolytic virus vaccine, both as monotherapy and in combination with PD‑1/PD‑L1 inhibitors. The study is ongoing and recruiting patients with advanced solid tumors; no published efficacy results yet[3][4].
- Therapeutic areas
- Oncology
- Modalities
- Oncolytic virus vaccines (OVV)Combination immunotherapiesMonoclonal antibodies (in combination regimens)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
No major pharmaceutical partnerships publicly disclosed as of May 2025.
Beyond the preview
Go deeper on Joint Biosciences Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Joint Biosciences Ltd..